MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2022

Continued strong recruitment in the dose escalation part of the fostrox study.   October – December Financial summary for the quarter · Net turnover amounted to SEK 2.3 (13.9) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -17.9 (-23.5) million. Basic and diluted earnings per share amounted to SEK -0.32 (-0.44) and SEK -0.32 (-0.44) respectively. · Cash flow from operating activities amounted to SEK -24.7 (-5.4) million. · Cash and cash equivalents at the end of the period amounted to SEK 117.4 (221.2) million.